Tumor-associated macrophages as a prognostic parameter in multiple myeloma

CD163 versus CD68 in tumor associated macrophages of classical hodgkin lymphoma

(2012) Jonathan A Harris et al.   Diagnostic Pathology

Immunohistochemical markers for tumor associated macrophages and survival in advanced classical Hodgkin's lymphoma

(2012) B. Sanchez-Espiridion et al.   HAEMATOLOGICA

Differential macrophage programming in the tumor microenvironment

(2012) Brian Ruffell et al.   TRENDS IN IMMUNOLOGY

Lack of association of tumor-associated macrophages with clinical outcome in patients with classical Hodgkin's lymphoma

(2011) D. Azambuja et al.   ANNALS OF ONCOLOGY

M2-Polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma

(2011) Bicheng Zhang et al.   Clinics

Tumour-associated macrophages in diffuse large B-cell lymphoma: a study of the Osaka Lymphoma Study Group

(2011) Naoki Wada et al.   HISTOPATHOLOGY

Tumour-infiltrating macrophages and clinical outcome in breast cancer

(2011) S M A Mahmoud et al.   JOURNAL OF CLINICAL PATHOLOGY

B cells and macrophages in cancer: yin and yang

(2011) Alberto Mantovani   NATURE MEDICINE

Refined Prognostic Role of CD68-Positive Tumor Macrophages in the Context of the Cellular Micromilieu of Classical Hodgkin Lymphoma

(2011) Alexandar Tzankov et al.   PATHOBIOLOGY

Role of tumor-associated macrophages in the progression of hepatocellular carcinoma

(2011) Ken Shirabe et al.   SURGERY TODAY

Prognostic implication of types of tumor-associated macrophages in Hodgkin lymphoma

(2011) Mona A. A. Zaki et al.   VIRCHOWS ARCHIV

The Number of Lymphoma-associated Macrophages in Tumor Tissue Is an Independent Prognostic Factor in Patients With Follicular Lymphoma

(2011) Bosko Andjelic et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

New Insights into Therapeutic Targets in Myeloma

(2011) K. C. Anderson   Hematology-American Society of Hematology Education Program

Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer

(2010) Norio Nonomura et al.   BJU INTERNATIONAL

Increased angiogenic sprouting in poor prognosis FL is associated with elevated numbers of CD163+ macrophages within the immediate sprouting microenvironment

(2010) A. J. Clear et al.   BLOOD

Macrophages, innate immunity and cancer: balance, tolerance, and diversity

(2010) Alberto Mantovani et al.   CURRENT OPINION IN IMMUNOLOGY

Tumor-infiltrating macrophages correlate with adverse prognosis and Epstein-Barr virus status in classical Hodgkin's lymphoma

(2010) P. Kamper et al.   HAEMATOLOGICA

Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm

(2010) Subhra K Biswas et al.   NATURE IMMUNOLOGY

Tumor-Associated Macrophages and Survival in Classic Hodgkin's Lymphoma

(2010) Christian Steidl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis

(2009) Y. Zheng et al.   BLOOD

Significance of M2-Polarized Tumor-Associated Macrophage in Pancreatic Cancer

(2009) Hiroshi Kurahara et al.   JOURNAL OF SURGICAL RESEARCH

The inflammatory micro-environment in tumor progression: The role of tumor-associated macrophages

(2008) Paola Allavena et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection

(2008) Tong Ding et al.   HUMAN PATHOLOGY

Bone marrow microenvironment and the identification of new targets for myeloma therapy

(2008) K Podar et al.   LEUKEMIA

Expression of CD68 tumor-associated macrophages in patients with diffuse large B-cell lymphoma and its relation to prognosis

(2008) Sverker Hasselblom et al.   PATHOLOGY INTERNATIONAL

Macrophage polarization in tumour progression

(2008) Antonio Sica et al.   SEMINARS IN CANCER BIOLOGY

High Numbers of Tumor-Associated Macrophages Have an Adverse Prognostic Value That Can Be Circumvented by Rituximab in Patients With Follicular Lymphoma Enrolled Onto the GELA-GOELAMS FL-2000 Trial

(2007) Danielle Canioni et al.   JOURNAL OF CLINICAL ONCOLOGY